Diagnosis and treatment information for prostate cancer remains a difficult problem. Current methods in diagnosis include some combination of rectal exam, blood analysis, MRI, CT, and ultrasound. Medical practitioners are often left with difficult decisions regarding which tests to order, both for discovery of prostate cancer cells as well as treatment. Much of the issues arise from a high rate of false positives that occur in the traditional PSA blood analysis test.
To combat these issues, researchers have begun creating efficient biomarker targeting compounds to be used in PET and SPECT scans. Visualizing cancerous growth has a number of advantages and can be both more accurate and meaningful than traditional diagnostic methods. Two of the most promising biomarkers for prostate cancer cells have been separately used successfully to diagnose prostate cancer.
However, it has recently been shown that these biomarkers have their own problems. The biomarker levels appear to change in patients based upon several factors. For instance, cancer growth patterns and the age of a tumor can affect levels. As a result, imaging based upon only one of the two biomarkers may be insufficient to capture the full range of prostate cancer, especially if a patient’s cancer has metastasized.
POTENTIAL AREAS OF APPLICATIONS:
• Prostate Cancer
• Target Treatments
MAIN ADVANTAGES OF INVENTION:
• Low Cost
STATE OF DEVELOPMENT:
• Patent Application in Work